edoc

Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1 : a multicenter, open-label study

Battegay, Manuel and Arasteh, Keikawus and Plettenberg, Andreas and Bogner, Johannes R. and Livrozet, Jean-Michel and Witt, Mallory D. and Mossdorf, Erik and Yong, Chan-Loi and Zhang, Wei and Macha, Sreeraj and Berger, Frank and Stern, Jerry and Robinson, Patrick and Quinson, Anne-Marie. (2011) Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1 : a multicenter, open-label study. Clinical therapeutics, Vol. 33, H. 9. pp. 1308-1320.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6004769

Downloads: Statistics Overview

Abstract

Nevirapine (NVP) is a widely used non-nucleoside reverse transcriptase inhibitor. A once-daily extended-release (XR) formulation would potentially increase adherence and thus efficacy.
Faculties and Departments:03 Faculty of Medicine > Departement Biomedizin > Department of Biomedicine, University Hospital Basel > Infection Biology (Khanna)
UniBasel Contributors:Battegay, Manuel E.
Item Type:Article, refereed
Article Subtype:Research Article
Bibsysno:Link to catalogue
Publisher:Excerpta Medica
ISSN:0149-2918
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:16 Aug 2013 07:34
Deposited On:16 Aug 2013 07:32

Repository Staff Only: item control page